Publication Name	World Journal of Methodology
Manuscript ID	15820
Country	Australia

Received	2014-12-10 16:58
Peer-Review Started	2014-12-12 08:24
To Make the First Decision	2015-01-08 14:08
Return for Revision	2015-01-17 13:20
Revised	2015-09-07 00:00
Second Decision	2015-10-10 19:32
Accepted by Journal Editor-in-Chief	2015-10-11 01:11
Accepted by Executive Editor-in-Chief	2015-10-27 18:14
Articles in Press	2015-10-27 18:14
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-12-03 13:13
Publish the Manuscript Online	2015-12-15 10:10

ISSN	2222-0682 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Methodology
Manuscript Type	Editorial
Article Title	Toward phase 4 trials in heart failure: A social and corporate responsibility of the medical profession
Manuscript Source	Invited Manuscript
All Author List	Pupalan Iyngkaran and Glen S Beneby
Funding Agency and Grant Number
Corresponding Author	Dr. Pupalan Iyngkaran, MBBS, FRACP, Consultant Cardiologist, NT Medical School, Research Fellow and Senior Lecturer Flinders University, PO Box 41326, Casuarina, Darwin NT 0815, Australia. gbeneby@batelnet.bs
Key Words	Clinical trial; Corporate responsibility; Health system; Congestive heart failure; Phase 4
Core Tip	This commentary brings needed and timely attention to phase 4 or postmarketing surveillance. Only a handful of congestive heart failure (CHF) therapies have actually been studied in the community after the randomized controlled trial. In this millennium it is important we not only innovate and support trials of new therapies, but also ensure the therapies we are already using are effective for all patients. As drug discovery and randomised controlled trial evidence is often done by private sector pharmaceuticals, we thus feel the need to bring attention on treating health care teams to regularly generate efficacy and effectiveness data for the CHF treatments they prescribe.
Publish Date	2015-12-15 10:10
Citation	Iyngkaran P, Beneby GS. Toward phase 4 trials in heart failure: A social and corporate responsibility of the medical profession. World J Methodol 2015; 5(4): 179-184
URL	http://www.wjgnet.com/2222-0682/full/v5/i4/179.htm
DOI	http://dx.doi.org/10.5662/wjm.v5.i4.179

Full Article (PDF)	WJM-5-179.pdf
Full Article (Word)	WJM-5-179.doc
Manuscript File	15820-Review.doc
Answering Reviewers	15820-Answering reviewers.pdf
Audio Core Tip	15820-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	15820-Conflict-of-interest statement.pdf
Copyright License Agreement	15820-Copyright assignment.pdf
Peer-review Report	15820-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	15820-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	15820-Scientific misconduct check.pdf
Scientific Editor Work List	15820-Scientific editor work list.pdf